menu search

LGND / 2 Medical Stocks to Buy Before Earnings

2 Medical Stocks to Buy Before Earnings
Cardinal Health (CAH) and Ligand Pharmaceuticals (LGND) are two healthcare companies that investors certainly want to watch going into their quarterly reports. Read More
Posted: May 2 2023, 22:12
Author Name: Zacks Investment Research
Views: 112220

LGND News  

Ligand Pharmaceuticals (LGND) Laps the Stock Market: Here's Why

By Zacks Investment Research
November 1, 2023

Ligand Pharmaceuticals (LGND) Laps the Stock Market: Here's Why

In the most recent trading session, Ligand Pharmaceuticals (LGND) closed at $53.30, indicating a +1.93% shift from the previous trading day. more_horizontal

Why Ligand Pharmaceuticals (LGND) is a Top Value Stock for the Long-Term

By Zacks Investment Research
October 24, 2023

Why Ligand Pharmaceuticals (LGND) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Pre more_horizontal

Ligand Pharmaceuticals (LGND) Sees a More Significant Dip Than Broader Market: Some Facts to Know

By Zacks Investment Research
October 20, 2023

Ligand Pharmaceuticals (LGND) Sees a More Significant Dip Than Broader Market: Some Facts to Know

In the closing of the recent trading day, Ligand Pharmaceuticals (LGND) stood at $52.09, denoting a -1.31% change from the preceding trading day. more_horizontal

Ligand Pharmaceuticals (LGND) Exceeds Market Returns: Some Facts to Consider

By Zacks Investment Research
October 9, 2023

Ligand Pharmaceuticals (LGND) Exceeds Market Returns: Some Facts to Consider

In the most recent trading session, Ligand Pharmaceuticals (LGND) closed at $58.84, indicating a +1.19% shift from the previous trading day. more_horizontal

Will Ligand (LGND) Beat Estimates Again in Its Next Earnings Report?

By Zacks Investment Research
October 9, 2023

Will Ligand (LGND) Beat Estimates Again in Its Next Earnings Report?

Ligand (LGND) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat i more_horizontal

Ligand (LGND) Acquires Certain Assets of Novan for $12.2M

By Zacks Investment Research
September 28, 2023

Ligand (LGND) Acquires Certain Assets of Novan for $12.2M

Following the acquisition, Ligand (LGND) has full ownership rights to berdazimer gel, all assets related to NITRICIL drug delivery technology platform more_horizontal

Ligand (LGND) to Spin Out Pelican Subsidiary, Updates '23 View

By Zacks Investment Research
September 19, 2023

Ligand (LGND) to Spin Out Pelican Subsidiary, Updates '23 View

Ligand (LGND) intends to spin out and merge its subsidiary Pelican with Primordial Genetics to form a new standalone company. Post-merger, it will own more_horizontal

Ligand: Nothing Exciting Stands Out

By Seeking Alpha
September 1, 2023

Ligand: Nothing Exciting Stands Out

Ligand Pharmaceuticals Incorporated generates revenue through licensing technologies, contractual fees, and the sale of Captisol, a modified cyclodext more_horizontal


Search within

Pages Search Results: